2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.
Leonard Gomella, MD, professor, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy in bladder cancer.
Urologists have been using immune-based agents in the urinary tract for 20 to 30 years, making the bladder a natural home for immunotherapy, says Gomella.
Newer studies are focusing on the mechanisms of immunotherapy—determining that it fights cancers. Additionally, Gomella says, newer agents are geared more toward the systemic treatment of patients with advanced bladder cancer rather than localized disease, but those agents are in the pipeline.